Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • 法伯氏病
Normal T1 Mapping Values Rule Out Adverse Cardiovascular Events in Fabry Cardiomyopathy: A New Multimodal Prognostic Score
Posted inCardiology news Radiology

Normal T1 Mapping Values Rule Out Adverse Cardiovascular Events in Fabry Cardiomyopathy: A New Multimodal Prognostic Score

Posted by MedXY By MedXY 01/05/2026
A prospective study of 167 Fabry disease patients identifies low T1 values, left ventricular hypertrophy, and late gadolinium enhancement as key predictors of major adverse cardiac events, leading to a robust new 3-year clinical prognostic score.
Read More
A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk
Posted inCardiology Nephrology news

A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk

Posted by MedXY By MedXY 01/05/2026
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
Read More
  • Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial
  • Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer
  • Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer
  • HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation
  • Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in